FY2025 EPS Estimates for BCYC Raised by Cantor Fitzgerald

Bicycle Therapeutics plc (NASDAQ:BCYC) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a research report issued on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($3.49) per share for the year, up from their previous forecast of ($4.24). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Several other equities research analysts also recently issued reports on BCYC. Stephens reissued an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. B. Riley reduced their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities reduced their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Trading Down 0.5 %

Shares of Bicycle Therapeutics stock opened at $10.97 on Friday. The stock has a 50-day moving average price of $13.27 and a 200 day moving average price of $19.40. The company has a market cap of $757.43 million, a P/E ratio of -3.33 and a beta of 0.93. Bicycle Therapeutics has a 1 year low of $10.81 and a 1 year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10. The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.16) EPS.

Insiders Place Their Bets

In other news, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at approximately $482,190. This represents a 7.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the acquisition, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 27,677 shares of company stock valued at $392,413 in the last three months. Insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at about $34,000. Barclays PLC grew its holdings in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the 4th quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.